Biotech Values

[rfj1862]

IMM

Woohoo! This just made a long, long day of teleconferences so much brighter. I love a man in uniform.

No I do not own this. I just thought it was ridiculous.


General Wesley Clark Joins Immtech as Consulting Strategic Advisor
Monday September 10, 9:02 am ET

NEW YORK, Sept. 10 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM - News) is pleased to announce today that General Wesley Clark (ret.) has joined Immtech as a strategic advisor. General Clark will provide counsel to Immtech's management team as the Company develops its drug programs targeting various global health challenges, including malaria prevention and treatment.

General Clark is one of the country's most distinguished retired military officers and a respected international voice in public affairs and diplomacy. He served as NATO Supreme Allied Commander from 1997 to 2000 and commanded troops in the campaign to end the Kosovo War, and he played a pivotal role in negotiating the Dayton Peace Accords to end the war in Bosnia.

"I am truly impressed by the private/public partnerships that Immtech has created as part of its effective business model to develop new treatments for global diseases," said General Clark. "I look forward to working closely with Immtech's leadership as the Company advances Immtech's promising drug pipeline."

General Clark served for 33 years with the United States Army, rising to the rank of 4-star general. He is a recipient of the Silver Star, Bronze Star, and Purple Heart, along with honorary Knighthoods from the British and Dutch governments. He was also made a commander of the French Legion of Honor, and in 2000 he was awarded the Presidential Medal of Freedom, the nation's highest civilian honor.

"We are honored to have General Clark join Immtech in this strategic advisory role," said Eric L. Sorkin, Immtech's Chairman and Chief Executive Officer. "General Clark will enhance Immtech's strategic work with international companies, foundations and governments. Few people have a better understanding of international cooperation, and we stand to benefit greatly from General Clark's expertise."

General Clark graduated top of his class from the United States Military Academy at West Point, and he holds a Master's Degree from Oxford University where he was a Rhodes Scholar. He was a U.S. presidential candidate in the 2004 election and is presently Chairman and CEO of Wesley K. Clark & Associates, a strategic advisory and consulting firm. He is also Chairman of Rodman and Renshaw, a New York based investment bank.

Immtech's first oral drug candidate, pafuramidine maleate, is currently in two phase II clinical trials for treatment and prevention of malaria. Each year malaria kills over one million people. It is also a significant threat to 125 million people who travel annually from developed countries to malaria endemic areas. Pafuramidine is also in two pivotal Phase III trials targeting the treatment of Pneumocystis pneumonia (PCP), a severe form of fungal infection in the lungs, and African sleeping sickness.

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases. Immtech has advanced clinical programs that include new treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (African sleeping sickness), and a well defined, expanding library of compounds targeting Hepatitis C, fungal infections, and bacterial infections. Immtech holds exclusive worldwide licenses to certain patents, patent applications and technology for products derived from a proprietary pharmaceutical platform. For additional information, please go to http://www.immtechpharma.com.